Volume 11, Issue 2 ( June 2019 2019)                   Iranian Journal of Blood and Cancer 2019, 11(2): 51-56 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bordbar M, Saleh F, Zekavat O R, Basiratnia M, Fathpour G, Zareifar S, et al . Deferoxamine Protective Effect in Preventing Nephrotoxicity in Children Under Treatment with Doxorubicin: A Randomized Clinical Trial. Iranian Journal of Blood and Cancer 2019; 11 (2) :51-56
URL: http://ijbc.ir/article-1-878-en.html
1- Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2- Bushehr University of Medical Sciences, Bushehr, Iran
3- Assistant Professor of Pediatric Hematology and Oncology, Bushehr University of Medical Sciences, Bushehr, Iran , nshakibazad@gmail.com
Abstract:   (3652 Views)
Background: Nephrotoxicity secondary to doxorubicin (DOX) may be associated with high morbidity and mortality rates. We aimed to assess the efficacy of Deferoxamine (DFO) in preventing DOX-induced nephrotoxicity in pediatric malignancy.
Methods: This Parallel-group randomized clinical trial was done on 62 children aged 2-18 years who had new onset malignancy treated with DOX. They were randomly assigned in three groups; group 1 (no intervention, n=21), group II (DFO 10 times DOX dose, n=20), group III (DFO 50mg/kg, n=21). Patients in the intervention groups received DFO concomitant with DOX 8-hour intravenous infusion in each chemotherapy course. Blood urea nitrogen, serum creatinine, electrolytes, calcium, phosphorus, magnesium and albumin levels, urine microalbumin, urine protein/creatinine ratio, and urine N-acetyl-β-D- glucosaminidase (NAG) as well as findings of kidney ultrasonography were compared between the groups after the last course of chemotherapy. The primary outcome was to compare the radiologic and serologic markers of glomerular and tubular damage between the 3 groups.
Results: Sixty patients were analyzed. Patients treated with DFO 10 times the dose of DOX had significantly lower urine NAG level compared to the control group (P=0.032). No significant renal damage was reported in their ultrasonography in the 3 groups. DFO was safely tolerated without any adverse effect.
Conclusion: DFO with 10-times the DOX dose may effectively prevent DOX-induced nephrotoxicity at least at the molecular level. Increasing the dose of DFO is not accompanied by better efficacy.
Trial registration: IRCT2016021915666N3
Full-Text [PDF 521 kb]   (1559 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2019/02/14 | Accepted: 2019/07/21 | Published: 2019/08/17

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb